A citation-based method for searching scientific literature

I S Nijhof, R W J Groen, H M Lokhorst, B van Kessel, A C Bloem, J van Velzen, R de Jong-Korlaar, H Yuan, W A Noort, S K Klein, A C M Martens, P Doshi, K Sasser, T Mutis, N W C J van de Donk. Leukemia 2015
Times Cited: 169







List of co-cited articles
878 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Inger S Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy E Axel, Khaja Syed, Richard W J Groen, Mark van Duin, Pieter Sonneveld, Monique C Minnema,[...]. Blood 2016
212
59

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Jakub Krejcik, Tineke Casneuf, Inger S Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W C J van de Donk, Brendan M Weiss,[...]. Blood 2016
512
58

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
Michel de Weers, Yu-Tzu Tai, Michael S van der Veer, Joost M Bakker, Tom Vink, Daniëlle C H Jacobs, Lukas A Oomen, Matthias Peipp, Thomas Valerius, Jerry W Slootstra,[...]. J Immunol 2011
645
47

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos,[...]. N Engl J Med 2016
925
43

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Mieczyslaw Komarnicki, Kenshi Suzuki,[...]. N Engl J Med 2016
920
42

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Henk M Lokhorst, Torben Plesner, Jacob P Laubach, Hareth Nahi, Peter Gimsing, Markus Hansson, Monique C Minnema, Ulrik Lassen, Jakub Krejcik, Antonio Palumbo,[...]. N Engl J Med 2015
751
40

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Sagar Lonial, Brendan M Weiss, Saad Z Usmani, Seema Singhal, Ajai Chari, Nizar J Bahlis, Andrew Belch, Amrita Krishnan, Robert A Vescio, Maria Victoria Mateos,[...]. Lancet 2016
573
36

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Marije B Overdijk, Sandra Verploegen, Marijn Bögels, Marjolein van Egmond, Jeroen J Lammerts van Bueren, Tuna Mutis, Richard W J Groen, Esther Breij, Anton C M Martens, Wim K Bleeker,[...]. MAbs 2015
319
35

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
María-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Polina Kaplan,[...]. N Engl J Med 2018
570
32

CD38 antibodies in multiple myeloma: back to the future.
Niels W C J van de Donk, Paul G Richardson, Fabio Malavasi. Blood 2018
220
30

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Jakub Krejcik, Kris A Frerichs, Inger S Nijhof, Berris van Kessel, Jeroen F van Velzen, Andries C Bloem, Marloes E C Broekmans, Sonja Zweegman, Johan van Meerloo, René J P Musters,[...]. Clin Cancer Res 2017
102
30

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.
Estefanía García-Guerrero, Tea Gogishvili, Sophia Danhof, Martin Schreder, Celine Pallaud, Jose Antonio Pérez-Simón, Hermann Einsele, Michael Hudecek. Blood 2017
67
43

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
Niels W C J van de Donk, Saad Z Usmani. Front Immunol 2018
140
28

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.
H Jiang, C Acharya, G An, M Zhong, X Feng, L Wang, N Dasilva, Z Song, G Yang, F Adrian,[...]. Leukemia 2016
144
27

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach,[...]. N Engl J Med 2019
464
26

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Inger S Nijhof, Richard W J Groen, Willy A Noort, Berris van Kessel, Regina de Jong-Korlaar, Joost Bakker, Jeroen J L van Bueren, Paul W H I Parren, Henk M Lokhorst, Niels W C J van de Donk,[...]. Clin Cancer Res 2015
107
24

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Jutta Deckert, Marie-Cécile Wetzel, Laura M Bartle, Anna Skaletskaya, Victor S Goldmacher, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute,[...]. Clin Cancer Res 2014
204
23

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
Tineke Casneuf, Xu Steven Xu, Homer C Adams, Amy E Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner,[...]. Blood Adv 2017
110
23

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot,[...]. Lancet 2019
423
23

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
Marije B Overdijk, J H Marco Jansen, Maaike Nederend, Jeroen J Lammerts van Bueren, Richard W J Groen, Paul W H I Parren, Jeanette H W Leusen, Peter Boross. J Immunol 2016
173
22

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Ajai Chari, Attaya Suvannasankha, Joseph W Fay, Bertrand Arnulf, Jonathan L Kaufman, Jainulabdeen J Ifthikharuddin, Brendan M Weiss, Amrita Krishnan, Suzanne Lentzsch, Raymond Comenzo,[...]. Blood 2017
321
21

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
Xiaoyan Feng, Li Zhang, Chirag Acharya, Gang An, Kenneth Wen, Lugui Qiu, Nikhil C Munshi, Yu-Tzu Tai, Kenneth C Anderson. Clin Cancer Res 2017
143
21

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
Michael S van der Veer, Michel de Weers, Berris van Kessel, Joost M Bakker, Shulamiet Wittebol, Paul W H I Parren, Henk M Lokhorst, Tuna Mutis. Haematologica 2011
160
20

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen,[...]. N Engl J Med 2015
912
20

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Saad Z Usmani, Brendan M Weiss, Torben Plesner, Nizar J Bahlis, Andrew Belch, Sagar Lonial, Henk M Lokhorst, Peter M Voorhees, Paul G Richardson, Ajai Chari,[...]. Blood 2016
275
19

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
Niels W C J van de Donk, Maarten L Janmaat, Tuna Mutis, Jeroen J Lammerts van Bueren, Tahamtan Ahmadi, A Kate Sasser, Henk M Lokhorst, Paul W H I Parren. Immunol Rev 2016
212
18

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Laura Moreno, Cristina Perez, Aintzane Zabaleta, Irene Manrique, Diego Alignani, Daniel Ajona, Laura Blanco, Marta Lasa, Patricia Maiso, Idoia Rodriguez,[...]. Clin Cancer Res 2019
113
18

Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology.
Fabio Malavasi, Silvia Deaglio, Ada Funaro, Enza Ferrero, Alberto L Horenstein, Erika Ortolan, Tiziana Vaisitti, Semra Aydin. Physiol Rev 2008
571
17

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos,[...]. Lancet 2019
277
17

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells.
Yufeng Wang, Yibo Zhang, Tiffany Hughes, Jianying Zhang, Michael A Caligiuri, Don M Benson, Jianhua Yu. Clin Cancer Res 2018
69
23

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka,[...]. N Engl J Med 2019
719
15

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.
Pasquale L Fedele, Simon N Willis, Yang Liao, Michael S Low, Jai Rautela, David H Segal, Jia-Nan Gong, Nicholas D Huntington, Wei Shi, David C S Huang,[...]. Blood 2018
45
33

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Yu-Tzu Tai, Myles Dillon, Weihua Song, Merav Leiba, Xian-Feng Li, Peter Burger, Alfred I Lee, Klaus Podar, Teru Hideshima, Audie G Rice,[...]. Blood 2008
358
14

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson,[...]. J Clin Invest 2019
334
14

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
Estefanía García-Guerrero, Ralph Götz, Sören Doose, Markus Sauer, Alfonso Rodríguez-Gil, Thomas Nerreter, K Martin Kortüm, José A Pérez-Simón, Hermann Einsele, Michael Hudecek,[...]. Leukemia 2021
29
48

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Karen L Bride, Tiffaney L Vincent, Soo-Yeon Im, Richard Aplenc, David M Barrett, William L Carroll, Robin Carson, Yunfeng Dai, Meenakshi Devidas, Kimberly P Dunsmore,[...]. Blood 2018
106
13

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Yu-Tzu Tai, Patrick A Mayes, Chirag Acharya, Mike Y Zhong, Michele Cea, Antonia Cagnetta, Jenny Craigen, John Yates, Louise Gliddon, William Fieles,[...]. Blood 2014
279
13

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov,[...]. Lancet Oncol 2020
311
13

Human CD38: a (r)evolutionary story of enzymes and receptors.
S Deaglio, K Mehta, F Malavasi. Leuk Res 2001
202
12

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Robert O Carpenter, Moses O Evbuomwan, Stefania Pittaluga, Jeremy J Rose, Mark Raffeld, Shicheng Yang, Ronald E Gress, Frances T Hakim, James N Kochenderfer. Clin Cancer Res 2013
392
12

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Eric D Hsi, Roxanne Steinle, Balaji Balasa, Susann Szmania, Aparna Draksharapu, Benny P Shum, Mahrukh Huseni, David Powers, Amulya Nanisetti, Yin Zhang,[...]. Clin Cancer Res 2008
392
12

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Jeffrey A Zonder, Ann F Mohrbacher, Seema Singhal, Frits van Rhee, William I Bensinger, Han Ding, John Fry, Daniel E H Afar, Anil K Singhal. Blood 2012
275
11

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
Limo Chen, Lixia Diao, Yongbin Yang, Xiaohui Yi, B Leticia Rodriguez, Yanli Li, Pamela A Villalobos, Tina Cascone, Xi Liu, Lin Tan,[...]. Cancer Discov 2018
237
11

Multiple myeloma.
Antonio Palumbo, Kenneth Anderson. N Engl J Med 2011
11

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Alexander M Lesokhin, Stephen M Ansell, Philippe Armand, Emma C Scott, Ahmad Halwani, Martin Gutierrez, Michael M Millenson, Adam D Cohen, Stephen J Schuster, Daniel Lebovic,[...]. J Clin Oncol 2016
678
11

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Jennifer N Brudno, Irina Maric, Steven D Hartman, Jeremy J Rose, Michael Wang, Norris Lam, Maryalice Stetler-Stevenson, Dalia Salem, Constance Yuan, Steven Pavletic,[...]. J Clin Oncol 2018
397
11

BCMA is essential for the survival of long-lived bone marrow plasma cells.
Brian P O'Connor, Vanitha S Raman, Loren D Erickson, W James Cook, Lehn K Weaver, Cory Ahonen, Ling-Li Lin, George T Mantchev, Richard J Bram, Randolph J Noelle. J Exp Med 2004
703
11

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos, Michele Cavo, Joan Blade, Meletios A Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy,[...]. Lancet 2020
180
11

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Thomas Martin, Rachid Baz, Don M Benson, Nikoletta Lendvai, Jeffrey Wolf, Pamela Munster, Alexander M Lesokhin, Claudine Wack, Eric Charpentier, Frank Campana,[...]. Blood 2017
125
10

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model.
Alberto L Horenstein, Antonella Chillemi, Valeria Quarona, Andrea Zito, Ilaria Roato, Fabio Morandi, Danilo Marimpietri, Marina Bolzoni, Denise Toscani, Robert J Oldham,[...]. Cells 2015
74
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.